Intellia Therapeutics Statistics

Total Valuation

LON:0JBU has a market cap or net worth of GBP 988.06 million. The enterprise value is 568.23 million.

Market Cap	988.06M
Enterprise Value	568.23M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	115.83M
Shares Outstanding	n/a
Shares Change (YoY)	+9.22%
Shares Change (QoQ)	+6.22%
Owned by Insiders (%)	1.82%
Owned by Institutions (%)	88.19%
Float	110.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.09
PB Ratio	1.77
P/TBV Ratio	1.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.71
EV / Sales	13.46
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.85

Financial Position

The company has a current ratio of 6.21, with a Debt / Equity ratio of 0.13.

Current Ratio	6.21
Quick Ratio	5.57
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	-0.24
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -52.11% and return on invested capital (ROIC) is -31.32%.

Return on Equity (ROE)	-52.11%
Return on Assets (ROA)	-28.51%
Return on Invested Capital (ROIC)	-31.32%
Return on Capital Employed (ROCE)	-57.57%
Weighted Average Cost of Capital (WACC)	14.49%
Revenue Per Employee	106,197
Profits Per Employee	-822,960
Employee Count	403
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.17% in the last 52 weeks. The beta is 2.06, so LON:0JBU's price volatility has been higher than the market average.

Beta (5Y)	2.06
52-Week Price Change	+19.17%
50-Day Moving Average	10.92
200-Day Moving Average	11.95
Relative Strength Index (RSI)	46.51
Average Volume (20 Days)	38,779

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.93

Income Statement

In the last 12 months, LON:0JBU had revenue of GBP 42.80 million and -331.65 million in losses. Loss per share was -3.16.

Revenue	42.80M
Gross Profit	-262.13M
Operating Income	-356.14M
Pretax Income	-331.65M
Net Income	-331.65M
EBITDA	-348.74M
EBIT	-356.14M
Loss Per Share	-3.16

Full Income Statement

Balance Sheet

The company has 380.19 million in cash and 72.88 million in debt, with a net cash position of 425.45 million.

Cash & Cash Equivalents	380.19M
Total Debt	72.88M
Net Cash	425.45M
Net Cash Per Share	n/a
Equity (Book Value)	556.78M
Book Value Per Share	4.81
Working Capital	363.20M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -305.50 million and capital expenditures -1.48 million, giving a free cash flow of -306.97 million.

Operating Cash Flow	-305.50M
Capital Expenditures	-1.48M
Free Cash Flow	-306.97M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-832.16%
Pretax Margin	-774.94%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0JBU does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.22%
Shareholder Yield	-9.22%
Earnings Yield	-33.57%
FCF Yield	-31.07%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0JBU has an Altman Z-Score of -0.72 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.72
Piotroski F-Score	3